Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo para avaliar eventos adversos e como o telisotuzumabe vedotina (ABBV-399) infundido por via intravenosa (IV) se move pelo corpo como monoterapia em participantes adultos com câncer de pulmão não escamoso de células não pequenas (NSCLC) previamente tratado

20 de outubro de 2026 atualizado por: AbbVie

Um estudo global de fase 2, aberto, randomizado, de dois regimes de telisotuzumabe vedotina em indivíduos com superexpressão de c-Met previamente tratada, tipo selvagem de EGFR, câncer de pulmão de células não pequenas não escamoso localmente avançado/metastático

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.

Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.

Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

150

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • São Paulo, Brasil, 01323-020
        • Recrutamento
        • Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
    • Ceará
      • Fortaleza, Ceará, Brasil, 60810-180
        • Recrutamento
        • Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
    • Paraná
      • Curitiba, Paraná, Brasil, 80510-130
        • Recrutamento
        • Ictrials Pesquisa E Desenvolvimento /ID# 276681
    • Pará
      • Belém, Pará, Brasil, 66063-495
        • Recrutamento
        • Cto - Centro De Tratamento Oncologico /ID# 276699
    • Pernambuco
      • Recife, Pernambuco, Brasil, 50040-000
        • Recrutamento
        • Hospital De Cancer De Pernambuco /ID# 276104
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasil, 59075-740
        • Recrutamento
        • Liga Norte Riograndense Contra O Cancer /ID# 273183
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Brasil, 98700-000
        • Recrutamento
        • Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasil, 88020-210
        • Recrutamento
        • Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 101149
        • Recrutamento
        • Beijing Chest Tumor Hospital /ID# 271935
    • Fujian
      • Fuzhou, Fujian, China, 350014
        • Recrutamento
        • Fujian Province Cancer Hospital /ID# 276178
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Recrutamento
        • Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150081
        • Recrutamento
        • Harbin Medical University Cancer Hospital /ID# 271665
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Recrutamento
        • Henan Cancer Hospital /ID# 271927
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Recrutamento
        • Union Hospital - Tongji Medical College /ID# 271668
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Recrutamento
        • The First Affiliated Hospital of Nanchang University /ID# 271666
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Recrutamento
        • The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
    • Shandong
      • Linyi, Shandong, China, 276001
        • Recrutamento
        • LinYi Cancer Hospital /ID# 272068
    • Xinjiang
      • Ürümqi, Xinjiang, China, 830011
        • Recrutamento
        • Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
    • Central Singapore
      • Singapore, Central Singapore, Cingapura, 169611
        • Recrutamento
        • National Cancer Centre Singapore /ID# 271499
      • Singapore, Central Singapore, Cingapura, 119074
        • Recrutamento
        • National University Hospital /ID# 271700
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • Recrutamento
        • Ironwood Cancer and Research Center /ID# 276370
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Recrutamento
        • University of Arkansas for Medical Sciences /ID# 272923
    • California
      • Los Angeles, California, Estados Unidos, 90067
        • Recrutamento
        • Valkyrie Clinical Trials /ID# 271322
      • Los Angeles, California, Estados Unidos, 90025
        • Recrutamento
        • Start Los Angeles /ID# 284999
      • Oxnard, California, Estados Unidos, 93030
        • Recrutamento
        • FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Concluído
        • Yale New Haven Hospital /ID# 271584
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32256
        • Recrutamento
        • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
      • Ocala, Florida, Estados Unidos, 34474
        • Recrutamento
        • Ocala Oncology Center /ID# 273697
      • Pembroke Pines, Florida, Estados Unidos, 33028
        • Recrutamento
        • Memorial Hospital West /ID# 270313
      • St. Petersburg, Florida, Estados Unidos, 33701-4732
        • Recrutamento
        • Comprehensive Hematology Oncology /ID# 270422
      • St. Petersburg, Florida, Estados Unidos, 33705
        • Recrutamento
        • Florida Cancer Specialists - North /ID# 271995
      • West Palm Beach, Florida, Estados Unidos, 33401
        • Recrutamento
        • Florida Cancer Specialists - East /ID# 271993
    • Georgia
      • Athens, Georgia, Estados Unidos, 30607
        • Recrutamento
        • University Cancer and Blood Center /ID# 270969
      • Marietta, Georgia, Estados Unidos, 30060
        • Recrutamento
        • Northwest Georgia Oncology Centers /ID# 275374
      • Savannah, Georgia, Estados Unidos, 31404
        • Concluído
        • Memorial University Medical Center /ID# 272467
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96819
        • Recrutamento
        • Kaiser Permanente Moanalua Medical Center /ID# 272916
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60607
        • Recrutamento
        • University of Illinois Hospital and Health Sciences System /ID# 275345
      • Niles, Illinois, Estados Unidos, 60714
        • Recrutamento
        • Illinois Cancer Specialists /ID# 274678
      • Peoria, Illinois, Estados Unidos, 61637-0001
        • Recrutamento
        • OSF St. Francis Medical Center /ID# 281591
      • Springfield, Illinois, Estados Unidos, 62702
        • Recrutamento
        • Springfield Clinic - First /ID# 272576
    • Nebraska
      • Lincoln, Nebraska, Estados Unidos, 68506
        • Recrutamento
        • Nebraska Hematology-Oncology /ID# 272970
      • Omaha, Nebraska, Estados Unidos, 68130
        • Recrutamento
        • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
    • Nevada
      • Reno, Nevada, Estados Unidos, 89502
        • Recrutamento
        • Renown Regional Medical Center /ID# 273535
    • New Jersey
      • East Brunswick, New Jersey, Estados Unidos, 08816-4096
        • Recrutamento
        • Astera Cancer Care /ID# 272359
      • Teaneck, New Jersey, Estados Unidos, 07666
        • Recrutamento
        • Regional Cancer Care Associates /ID# 270783
    • New York
      • The Bronx, New York, Estados Unidos, 10461
        • Recrutamento
        • Montefiore Medical Center - Einstein Campus /ID# 277169
      • Westbury, New York, Estados Unidos, 11590
        • Recrutamento
        • Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
    • North Carolina
      • Pinehurst, North Carolina, Estados Unidos, 28374
        • Recrutamento
        • FirstHealth of the Carolinas- Speciality Center /ID# 272924
    • Ohio
      • Perrysburg, Ohio, Estados Unidos, 43551
        • Recrutamento
        • Mercy Health - Perrysburg Cancer Center /ID# 270536
      • Zanesville, Ohio, Estados Unidos, 43701
        • Recrutamento
        • Genesis Healthcare System /ID# 273361
    • Pennsylvania
      • Sayre, Pennsylvania, Estados Unidos, 18840
        • Recrutamento
        • Guthrie Robert Packer Hospital /ID# 270316
      • York, Pennsylvania, Estados Unidos, 17403
        • Recrutamento
        • Cancer Care Associates Of York /ID# 270971
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Recrutamento
        • Medical University of South Carolina /ID# 273272
      • Greenville, South Carolina, Estados Unidos, 29607
        • Recrutamento
        • Saint Francis Cancer Center - Greenville /ID# 276368
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Recrutamento
        • SCRI Oncology Partners /ID# 270162
    • Texas
      • Dallas, Texas, Estados Unidos, 75246
        • Recrutamento
        • Texas Oncology - Dallas - Worth Street /ID# 278947
      • Tyler, Texas, Estados Unidos, 75702
        • Recrutamento
        • Texas Oncology - Northeast Texas /ID# 272000
    • Utah
      • Ogden, Utah, Estados Unidos, 84405
        • Recrutamento
        • Community Cancer Trials Of Utah /ID# 276598
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Recrutamento
        • Virginia Cancer Specialists - Fairfax /ID# 272004
    • Washington
      • Spokane, Washington, Estados Unidos, 99208
        • Recrutamento
        • Medical Oncology Associates - Spokane /ID# 277172
      • Tacoma, Washington, Estados Unidos, 98405
        • Recrutamento
        • Northwest Medical Specialties Tacoma /ID# 270534
      • Haifa, Israel, 3109601
        • Recrutamento
        • Rambam Health Care Campus- Haifa /ID# 270078
      • Jerusalem, Israel, 9103102
        • Concluído
        • Shaare Zedek Medical Center /ID# 270095
    • Central District
      • Kefar Sava, Central District, Israel, 4428164
        • Recrutamento
        • Meir Medical Center /ID# 270071
      • Petah Tikva, Central District, Israel, 4941492
        • Recrutamento
        • Rabin Medical Center. /ID# 270087
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel, 5265601
        • Recrutamento
        • The Chaim Sheba Medical Center /ID# 270068
    • Aichi-ken
      • Nagoya, Aichi-ken, Japão, 466-8560
        • Recrutamento
        • Nagoya University Hospital /ID# 277010
    • Chiba
      • Kashiwa-shi, Chiba, Japão, 277-8577
        • Recrutamento
        • National Cancer Center Hospital East /ID# 277056
    • Hokkaido
      • Sapporo, Hokkaido, Japão, 060-8648
        • Recrutamento
        • Hokkaido University Hospital /ID# 277014
    • Hyōgo
      • Kobe, Hyōgo, Japão, 650-0046
        • Recrutamento
        • Kobe Minimally Invasive Cancer Center /ID# 277469
    • Kanagawa
      • Sagamihara-shi, Kanagawa, Japão, 252-0375
        • Recrutamento
        • Kitasato University Hospital /ID# 277012
    • Miyagi
      • Sendai, Miyagi, Japão, 981-0914
        • Recrutamento
        • Sendai Kousei Hospital /ID# 277023
    • Miyazaki
      • Miyazaki, Miyazaki, Japão, 889-1692
        • Recrutamento
        • University of Miyazaki Hospital /ID# 277020
    • Okayama-ken
      • Kurashiki-shi, Okayama-ken, Japão, 710-8602
        • Recrutamento
        • Kurashiki Central Hospital /ID# 276995
    • Shizuoka
      • Fujieda, Shizuoka, Japão, 426-0077
        • Recrutamento
        • Fujieda Municipal General Hospital /ID# 277025
    • Wakayama
      • Wakayama, Wakayama, Japão, 641-8510
        • Recrutamento
        • Wakayama Medical University Hospital /ID# 276997
    • Beograd
      • Belgrade, Beograd, Sérvia, 11000
        • Recrutamento
        • Institute for Oncology and Radiology of Serbia /ID# 270561
      • Belgrade, Beograd, Sérvia, 11080
        • Recrutamento
        • Clinical Hospital Center - Bezanijska Kosa /ID# 270558
      • Belgrade, Beograd, Sérvia, 11000
        • Recrutamento
        • University Clinical Center Serbia /ID# 270808
      • Belgrade, Beograd, Sérvia, 11000
        • Recrutamento
        • Military Medical Academy /ID# 279873
    • Nisavski Okrug
      • Niš, Nisavski Okrug, Sérvia, 18300
        • Recrutamento
        • University Clinical Center Nis /ID# 270557
    • Sremski Okrug
      • Kamenitz, Sremski Okrug, Sérvia, 21208
        • Recrutamento
        • Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
    • Sumadijski Okrug
      • Kragujevac, Sumadijski Okrug, Sérvia, 34000
        • Recrutamento
        • University Clinical Center Kragujevac /ID# 275773

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Projected life expectancy of at least 12 weeks.
  • Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
  • Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
  • Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
  • Actionable alterations in genes other than EGFR are permitted.
  • Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
  • Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
  • Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.

Exclusion Criteria:

  • Adenosquamous or neuroendocrine histology, or sarcomatoid features.
  • EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
  • Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
  • Received prior docetaxel therapy.
  • Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
  • History of other malignancies except those stated in the protocol.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
  • Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
  • Major surgery within 21 days prior to randomization.
  • Clinically significant condition(s) including but not limited to those listed in the protocol.
  • Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
  • Grade >= 2 edema or lymphedema.
  • Grade >= 2 ascites or pleural effusion.
  • Grade >= 2 neuropathy.
  • Active uncontrolled bacterial or viral infection.
  • Active corneal disorder.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Telisotuzumab Vedotin Dose A

Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration.

Intravenous (IV) Infusion

Outros nomes:
  • ABBV-399
Experimental: Telisotuzumab Vedotin Dose B

Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration.

Intravenous (IV) Infusion

Outros nomes:
  • ABBV-399
Experimental: Telisotuzumab Vedotin Dose C

Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration.

Intravenous (IV) Infusion

Outros nomes:
  • ABBV-399

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Prazo: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Prazo: Up to Approximately 3 Years

ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2).

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Prazo: Up to Approximately 3 Years

Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2)

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Prazo: Up to Approximately 3 Years

Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2).

Up to Approximately 3 Years
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Prazo: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Prazo: Up to Approximately 3 Years

An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device.

Up to Approximately 3 Years
Objective Response (OR) by Blinded Independent Central Review (BICR)
Prazo: Up to Approximately 3 Years

OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1.

Up to Approximately 3 Years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Prazo: Up to 26 Weeks

Concentrations of telisotuzumab vedotin conjugate in serum.

Up to 26 Weeks
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Prazo: Up to 26 Weeks

Concentrations of MMAE payload in plasma.

Up to 26 Weeks
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Prazo: Up to 26 Weeks

Percentage of participants with ADAs of telisotuzumab vedotin.

Up to 26 Weeks
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Prazo: Up to 26 Weeks

Percentage of participants with nADAs of telisotuzumab vedotin.

Up to 26 Weeks
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Prazo: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years

The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present).

Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Prazo: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years

The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants.

Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
Duration of Response (DoR) by BICR
Prazo: Up to Approximately 3 Years

DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause.

Up to Approximately 3 Years
Progression-Free Survival (PFS) by BICR
Prazo: Up to Approximately 3 Years

PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause.

Up to Approximately 3 Years
Overall Survival (OS)
Prazo: Up to Approximately 3 Years

OS will be defined as the time from randomization to death from any cause.

Up to Approximately 3 Years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: ABBVIE INC., AbbVie

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de janeiro de 2025

Conclusão Primária (Estimado)

1 de fevereiro de 2028

Conclusão do estudo (Estimado)

1 de fevereiro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

22 de agosto de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de agosto de 2024

Primeira postagem (Real)

23 de agosto de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Prazo de Compartilhamento de IPD

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Critérios de acesso de compartilhamento IPD

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever